WED-235 Prediction of metabolic dysfunction-associated steatohepatitis resolution
Rohit Loomba(University of California San Diego), Daniel Tsung‐Ning Huang, Maral Amangurbanova(University of California San Diego), Shibao Feng, Harris Siddiqi(University of California San Diego), Ricki Bettencourt(University of California San Diego), Mildred D. Gottwald(Mountain View Clinical Research), Maya Margalit(IDEA Bio-Medical (Israel)), Lisa Richards(University of California San Diego), Egbert Madamba(University of California San Diego)
Cited by 0
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k